Figure 1
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
14. August 2024 08:30 ET | Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Vaccinex logo
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
17. Juli 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
Vaccinex logo
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
06. Juni 2024 08:30 ET | Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Vaccinex logo
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
15. Mai 2024 18:00 ET | Vaccinex, Inc.
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.
Vaccinex logo
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
07. Februar 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
US Neurologists Opti
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
03. Januar 2024 09:46 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
Vaccinex logo
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13. November 2023 08:00 ET | Vaccinex, Inc.
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
22. September 2023 16:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex logo
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
15. Mai 2023 16:45 ET | Vaccinex, Inc.
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...
Vaccinex logo
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25. April 2023 08:00 ET | Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....